Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Actuate Therapeutics IncNASDAQ: ACTU
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $5.63M (cash outflow) fell 10.9% year over year, ahead of the -14.9% change in trailing-twelve-month net income. Sequentially, it rose 23.5% from the prior quarter. Over 3 fiscal years it compounded at +3.3% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate of -$16.87M (-24.1%) for the fiscal year ending Dec 2026, a slowdown from the -18.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$5.63M+23.5% QoQ
- Last fiscal yearDec 2025
- -$22.23M-18.5% YoY
- LTMMar 2026
- -$21.54M-14.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.9% | -21.6% | -10.7 pp |
| 1 year | -18.5% | -24.1% | -5.6 pp |
| 3-year CAGR | +3.3% | -4.1% | -7.4 pp |
| 5-year CAGR | -31.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (22.23M) USD
- Year-over-year change
- +18.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.23M) | +18.5% |
| FY2024 | 2024-12-31 | (27.29M) | -10.3% |
| FY2023 | 2023-12-31 | (24.74M) | -22.7% |
| FY2022 | 2022-12-31 | (20.16M) | — |
Net Income vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -14.9% is the 6th highest of 9, against a peer median of -4.3%.
- Over three fiscal years its annual growth of +3.3% compares with a peer median of +9.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $883.08M USD | +644.6% | +96.2% | — | |
| LTM Mar 2026 | $125.39M USD | +1.6% | +2.3% | 680.8% | |
| LTM Mar 2026 | $99.93M USD | -10.2% | -2.9% | — | |
| LTM Mar 2026 | $77.22M USD | -24.4% | +9.1% | — | |
| LTM Mar 2026 | CHF 64.16M CHF | +7.8% | — | — | |
| LTM Mar 2026 | $46.9M USD | -164.3% | — | 4088.8% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $40.19M USD | -21.6% | +11.9% | — |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $21.54M USD | -14.9% | +3.3% | — |
| LTM Mar 2026 | $15.24M USD | +121.8% | — | 27.8% | |
| Peer median (excluding ACTU) | — | -4.3% | +9.1% | 680.8% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (20.16M) | (24.74M) | (27.29M) | (22.23M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 654.07K | 423.54K | 2M | 6.05M |
| Change in Working Capital | 1.73M | 2.57M | 1.1M | (3.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 586.26K | 1.29M | (1.5M) | (512.54K) |
| Other Working Capital | 1.15M | 1.28M | 2.6M | (2.53M) |
| Other Non-Cash Items | (20.38K) | 123.46K | 2.35M | 20.25K |
| Operating Cash Flow | (17.79M) | (21.63M) | (21.84M) | (19.21M) |
| Capital Expenditures | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 5.5M | 0 |
| Common Stock Issued | 0 | 0 | 23.96M | 24.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (1.93M) | (302.83K) |
| Financing Cash Flow | 19.26M | 4.13M | 27.53M | 23.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.46M | (17.49M) | 5.68M | 4.52M |
| Free Cash Flow | (17.79M) | (21.63M) | (21.84M) | (19.21M) |
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.